Legend Biotech Announces Participation in Upcoming March 2023 Investor Conferences

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced its participation in the upcoming investor conferences.

SOMERSET, N.J.--(BUSINESS WIRE)-- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:

Event: Cowen 43rd Annual Healthcare Conference
Location: Boston, MA
Fireside Chat Date & Time: Tuesday, March 7, 2023 at 9:50am ET
Presenter: Ying Huang, Ph.D., CEO

Event: Barclays Global Healthcare Conference
Location: Miami, FL
Fireside Chat Date & Time: Tuesday, March 14, 2023 at 10:15am ET
Presenter: Ying Huang, Ph.D., CEO

About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230224005077/en/

Contacts

Press Contact:
Tina Carter, Corporate Communications Lead, Legend Biotech
tina.carter@legendbiotech.com
(908) 331-5025

Investor Contacts:
Joanne Choi, Senior Manager, Investor Relations, Legend Biotech
joanne.choi@legendbiotech.com

Crystal Chen, Manager, Investor Relations, Legend Biotech
crystal.chen@legendbiotech.com

Source: Legend Biotech

MORE ON THIS TOPIC